<i>SLCO1B1</i> variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritis

Roszkiewicz, Justyna; Michałek, Dominika; Рык, А. А.; Swacha, Zbigniew; Szmyd, Bartosz; Smolewska, Elżbieta

doi:10.1080/03009742.2020.1818821

Cited by 13 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These differences may be associated with variations in intensities of fear of infectious diseases and possible side-effects of vaccination. The difficulties may be also strengthened by the existence of a spectrum of childhood diseases which may be triggered and/or exacerbated by infectious agents but also vaccinations, e.g., juvenile idiopathic arthritis [ 41 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

Medical Students and SARS-CoV-2 Vaccination: Attitude and Behaviors

et al. 2021

View full text Add to dashboard Cite

Since physicians play a key role in vaccination, the initial training of medical students (MS) should aim to help shape their attitude in this regard. The beginning of vaccination programs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an excellent time to assess the attitudes held by both medical and non-medical students regarding vaccination. A 51- to 53-item questionnaire including the Depression, Anxiety and Stress Scale was administered to 1971 students (49.21% male; 34.86% MS); two career-related questions were also addressed to the MS. The majority of surveyed students indicated a desire to get vaccinated against SARS-CoV-2, with more medical than non-medical students planning to get vaccinated (91.99% vs. 59.42%). The most common concern about SARS-CoV-2 infection was the risk of passing on the disease to elderly relatives. While conspiracy theories regarding the COVID-19 vaccine are less popular among MS, both groups indicated concerns that vaccines may cause autism is equally common (~5%). Further studies exploring social attitudes towards the SARS-CoV-2 vaccine are a necessary first step to optimizing vaccination programs and achieving herd immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Medical Students and SARS-CoV-2 Vaccination: Attitude and Behaviors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The 1B1 * 15 haplotype, which includes SLCO1B1 * 5 (rs4149056, 521T > C) and SLCO1B1 * 1B (rs2306283, 388 A > G), has been identified as a risk factor for myopathy caused by multiple statins ( n = 7); lipid-lowering agents ( 54 ). This allele may possibly affect methotrexate-related toxicity, though the association evidence level is moderately low ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB

Alshabeeb

Alyabsi²,

Aziz³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundDifferent levels of evidence related to the variable responses of individuals to drug treatment have been reported in various pharmacogenomic (PGx) databases. Identification of gene-drug pairs with strong association evidence can be helpful in prioritizing the implementation of PGx guidelines and focusing on a gene panel. This study aimed to determine the pharmacogenes with the highest evidence-based association and to indicate their involvement in drug-gene interactions.MethodologyThe publicly available datasets CPIC, DPWG, and PharmGKB were selected to determine the pharmacogenes with the highest drug outcome associations. The upper two levels of evidence rated by the three scoring methods were specified (levels A–B in CPIC, 3–4 in DPWG, or 1–2 levels in PharmGKB). The identified pharmacogenes were further ranked in this study based on the number of medications they interacted with.ResultsFifty pharmacogenes, with high to moderately high evidence of associations with drug response alterations, with potential influence on the therapeutic and/or toxicity outcomes of 152 drugs were identified. CYP2D6, CYP2C9, CYP2C19, G6PD, HLA-B, SLCO1B1, CACNA1S, RYR1, MT-RNR1, and IFNL4 are the top 10 pharmacogenes, where each is predicted to impact patients' responses to ≥5 drugs.ConclusionThis study identified the most important pharmacogenes based on the highest-ranked association evidence and their frequency of involvement in affecting multiple drugs. The obtained data is useful for customizing a gene panel for PGx testing. Identifying the strength of scientific evidence supporting drug-gene interactions aids drug prescribers in making the best clinical decision.

show abstract

“…Другие полиморфизмы в гене SLCO1B1 также являются клинически значимыми. Маркеры rs4149056 (генотип TT или TC) и rs11045879 (генотип CC и TC) в гене SLCO1B1 связаны со снижением клиренса при высокодозной терапии МТХ в сочетании с более низкой частотой желудочно-кишечной токсичности и в некоторых случаях с повышенной нефро-и гепатотоксичностью [43]. Пациентам с генотипами повышенного риска могут быть рекомендованы более длительное защелачивание вводимых вместе с МТХ инфузионных растворов, более продолжительное проведение инфузионной терапии и введение фолината кальция [44].…”

Section: фармакогенетические предикторы токсичностиunclassified

Role of pharmacogenetic factors in the development of side effects of methotrexate in the treatment of malignant tumors: A review

et al. 2021

View full text Add to dashboard Cite

Methotrexate (MTX) is one of the main chemotherapeutic agents that has determined the high effectiveness of protocols for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphomas. The reverse side of the high anti-tumor activity of MTX is the adverse reactions, which require accompanying preventive therapy. But even modern accompanying therapy in some cases does not avoid severe toxicity from the skin and mucous membranes, nervous system, kidneys, liver. MTX pharmacokinetics exhibits significant individual variability, which may be a reflection of genetic variability. Numerous pharmacogenetic studies have evaluated the effect of polymorphism of various genes involved in MTX metabolism on MTX pharmacokinetics and the development of toxic manifestations in order to improve patient outcomes and decrease drug toxicity. This review presents impact of key metabolic MTX genes (ATIC, DHFR, GGH, FPGS, MTHFR, MTR, MTRR, TYMS) and transporter proteins genes (ABCB1, ABCG2, ABCC2, ABCC4, SLC19A1, SLCO1B1) in the development of MTX side effects. Polymorphic markers in SLCO1B1 gene have the most influence with MTX pharmacokinetic.

show abstract

SLCO1B1 variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritis

Cited by 13 publications

References 15 publications

Medical Students and SARS-CoV-2 Vaccination: Attitude and Behaviors

Medical Students and SARS-CoV-2 Vaccination: Attitude and Behaviors

Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB

Role of pharmacogenetic factors in the development of side effects of methotrexate in the treatment of malignant tumors: A review

Contact Info

Product

Resources

About